• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy.

作者信息

Szabo Agoston Gyula, Thorsen Jonathan, Iversen Katrine Fladeland, Levring Mette Bøegh, Preiss Birgitte, Helleberg Carsten, Breinholt Marie Fredslund, Hermansen Emil, Gjerdrum Lise Mette Rahbek, Bønløkke Søren Thorgaard, Nielsen Katrine, Kjeldsen Eigil, Teodorescu Elena Manuela, Dokhi Marveh, Kurt Eva, Strandholdt Casper Nørgaard, Andersen Mette Klarskov, Vangsted Annette Juul

机构信息

Department of Hematology, Vejle Hospital, Vejle, Denmark.

Department of Hematology Rigshospitalet, Copenhagen University, Copenhagen, Denmark.

出版信息

Am J Hematol. 2022 Mar 1;97(3):E117-E120. doi: 10.1002/ajh.26449. Epub 2021 Dec 29.

DOI:10.1002/ajh.26449
PMID:34967035
Abstract
摘要

相似文献

1
The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy.停用首个含达雷妥尤单抗治疗方案的多发性骨髓瘤患者的临床病程及预期寿命
Am J Hematol. 2022 Mar 1;97(3):E117-E120. doi: 10.1002/ajh.26449. Epub 2021 Dec 29.
2
NICE guidance on daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma.英国国家卫生与临床优化研究所（NICE）关于达雷妥尤单抗联合硼替佐米及地塞米松用于既往治疗过的多发性骨髓瘤的指南。
Lancet Oncol. 2019 May;20(5):619-620. doi: 10.1016/S1470-2045(19)30222-0. Epub 2019 Apr 10.
3
Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.达雷妥尤单抗、埃罗妥珠单抗与多发性骨髓瘤治疗性单克隆抗体的研发
Clin Pharmacol Ther. 2017 Jan;101(1):81-88. doi: 10.1002/cpt.550.
4
Daratumumab improves survival in multiple myeloma.达雷妥尤单抗可改善多发性骨髓瘤患者的生存率。
Lancet Oncol. 2016 Nov;17(11):e480. doi: 10.1016/S1470-2045(16)30503-4. Epub 2016 Oct 13.
5
Daratumumab in multiple myeloma.达雷妥尤单抗在多发性骨髓瘤中的应用。
Cancer. 2019 Jul 15;125(14):2364-2382. doi: 10.1002/cncr.32065. Epub 2019 Apr 5.
6
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.达雷妥尤单抗联合硼替佐米、美法仑和泼尼松治疗未经治疗的多发性骨髓瘤。
N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12.
7
How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma.如何将埃罗妥珠单抗和达雷妥尤单抗整合到多发性骨髓瘤的治疗中。
J Clin Oncol. 2016 Dec 20;34(36):4421-4430. doi: 10.1200/JCO.2016.69.5908. Epub 2016 Oct 31.
8
Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma.达雷妥尤单抗及其在复发和/或难治性多发性骨髓瘤治疗中的应用。
Future Oncol. 2018 Dec;14(30):3111-3121. doi: 10.2217/fon-2018-0275. Epub 2018 Aug 23.
9
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.达雷妥尤单抗联合泊马度胺和地塞米松与泊马度胺和地塞米松单药治疗既往治疗的多发性骨髓瘤（APOLLO）：一项开放标签、随机、III 期临床试验。
Lancet Oncol. 2021 Jun;22(6):801-812. doi: 10.1016/S1470-2045(21)00128-5.
10
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.达雷妥尤单抗、泊马度胺和地塞米松治疗复发或难治性骨髓瘤患者的临床疗效：在耐药患者中再次使用达雷妥尤单抗的效果。
Cancer. 2019 Sep 1;125(17):2991-3000. doi: 10.1002/cncr.32178. Epub 2019 May 15.

引用本文的文献

1
Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature review.复发/难治性多发性骨髓瘤中基于抗CD38再治疗的临床结局：一项系统文献综述
Front Oncol. 2025 Mar 12;15:1550644. doi: 10.3389/fonc.2025.1550644. eCollection 2025.
2
Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?复发/难治性多发性骨髓瘤患者中达雷妥尤单抗再治疗是否有作用？
Biomedicines. 2025 Jan 15;13(1):207. doi: 10.3390/biomedicines13010207.
3
The real-world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies.
泊马度胺在CD38抗体时代用于复发难治性多发性骨髓瘤的真实世界应用及疗效
EJHaem. 2023 Aug 24;4(4):1006-1012. doi: 10.1002/jha2.774. eCollection 2023 Nov.
4
Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59.从接受达雷妥尤单抗治疗的多发性骨髓瘤患者的血浆中分离出的细胞外囊泡表达 CD38、PD-L1 以及补体抑制蛋白 CD55 和 CD59。
Cells. 2022 Oct 25;11(21):3365. doi: 10.3390/cells11213365.